FDA to Expedite Review of Eli Lilly’s (LLY) New Manufacturing Facilities
TipRanks
Last updated: June 30, 2026
Eli Lilly and Company is set to have its new manufacturing facilities fast-tracked for review by the U.S. Food and Drug Administration (FDA). This expedited review is crucial as the company is undertaking a significant expansion of its production capabilities to meet anticipated demand.
- Eli Lilly is investing a substantial $27 billion to construct four new manufacturing plants. These facilities are strategically located to bolster the company's production capacity, primarily for its blockbuster weight-loss and diabetes drugs, including Mounjaro and Zepbound.
- The decision by the FDA to expedite the review process signals a recognition of the urgent need for increased supply of these critical medications. The expansion is expected to create thousands of jobs and significantly contribute to Eli Lilly's growth.
- The new plants are slated to be built in Indiana, North Carolina, and Germany. This global expansion aims to secure a more robust supply chain and cater to the growing international demand for Eli Lilly's innovative treatments.
- The substantial investment underscores the projected long-term demand for Lilly's key products and the company's commitment to scaling up production to ensure patient access.
